The Axcellant team recently returned from Orlando, where we attended the 30th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology (ASNC 2025).
This year’s edition once again proved to be a valuable opportunity to stay close to the evolving landscape of nuclear cardiology, connect with leading experts in the field, and engage in conversations that inform how we support our partners in clinical trial planning and operations.
While the primary focus of our visit was networking, several sessions stood out as particularly relevant to the challenges and opportunities we see in imaging-driven trials. One highlight was a panel discussion featuring physicians who have successfully developed focused clinical programs in areas such as amyloidosis, cardio-oncology, sarcoidosis, and women’s cardiology. These programs offered practical insight into how imaging can be meaningfully integrated into patient care and research — closely reflecting our own focus on trial design in complex, high-impact therapeutic areas.
We were also pleased to hold in-depth discussions with several outstanding experts in the field, including Prof. Piotr Słomka, Prof. Juhani Knuuti, Prof. Mouaz Al-Mallah, Prof. Andrew Einstein, Prof. Tim Bateman, and Prof. Prem Soman. These conversations helped us shape strategic directions for ongoing and upcoming imaging-focused studies.
Events like ASNC confirm that focusing on high-complexity, high-need therapeutic areas is not only a strategic decision, but also a meaningful contribution to improving care in cardiology and beyond.
Learn more about the event here.
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant